Long-term Prognosis of Emergency Aneurysmal Subarachnoid Hemorrhage

Condition(s) studied

Investigational drug(s) / intervention(s)

Surgical clipping and endovascular coiling: Surgical clipping: Apply aneurysm clip to clip the ruptured aneurysm. Endovascular coiling：Also called endovascular embolization, to block blood flow into an aneurysm.Preventing blood flow into an aneurysm helps to keep it from rupturing.

Study summary

Rupture of intracranial aneurysms can lead to extensive subarachnoid hemorrhage (SAH), a potentially fatal neurological emergency with mortality rates ranging from 8 to 67%. At present, surgical clipping (SC) and endovascular coiling (EC) are two main treatments for aneurysmal subarachnoid hemorrhage (aSAH), in recent years, the improvements in surgical equipment and techniques have already greatly improved the postoperative safety of patients. However, considering individual differences between patients, some still at risk due to possible complications during hospitalization or after discharge from the hospital, it will no doubt generate a large healthcare burden.

This prospective, observational clinical trial (LongTEAM) is to improve the diagnosis and treatment effect and efficiency in this field, reducing mortality, medical costs, and medical burden, while opening up new avenues for interdisciplinary clinical practice and scientific research exploration.

Eligibility

Primary outcome measure(s)

• Unfavorable neurological outcome (mRS>2) — 10 days after the procedure
  Number of patients experiencing a unfavorable neurological outcome at discharge, defined as a modified Rankin Scale (mRS) score of \>2.
• Unfavorable neurological outcome (mRS>2) — 3 months
  Number of patients experiencing a unfavorable neurological outcome at 3 months post-treatment, defined as a modified Rankin Scale (mRS) score of \>2.
• Unfavorable neurological outcome (mRS>2) — 6 months
  Number of patients experiencing a unfavorable neurological outcome at 6 months post-treatment, defined as a modified Rankin Scale (mRS) score of \>2.
• Unfavorable neurological outcome (mRS>2) — 12 months
  Number of patients experiencing a unfavorable neurological outcome at 12 months post-treatment, defined as a modified Rankin Scale (mRS) score of \>2.
• Unfavorable neurological outcome (mRS>2) — 24 months
  Number of patients experiencing a unfavorable neurological outcome at 24 months post-treatment, defined as a modified Rankin Scale (mRS) score of \>2.

Trial sites (2)

More Beijing Tiantan Hospital trials in China

Other trials for the same condition